EXTRAOSSEOUS ABNORMALITIES AND ARTIFACTS IN SKELETAL SCINTIGRAPHY

Objective: to specify frequency, patterns and diagnostic significance of extraosseous soft tissue findings in 99mTc-pyrophosphate skeletal scintigraphy. Material and methods. Results of skeletal scintigraphy from 1060 patients (447 men, 613 women) were analyzed. Scanning in "whole body" mode started in 3–4 hours after 740 MBq of radiotracer activity intravenous administration, and performed in anterior and posterior projections in continuous table motion mode at rate of 6–8 cm per minute. Single photon emission computed tomography/ computed tomography (SPECT/CT) was additionally performed when necessary. Results. Extraosseous scintigraphic findings were discovered in 161 (15.2%) patients, they can be divided into three categories: nephrourological (7.7%), soft tissue (5.4%) and artifacts (2.1%). First category included anatomical and functional changes in the urinary system (kidney location anomalies and nonobstructive uropathies). SPECT/CT was performed to differentiate calycostasis in the projection of the upper group of calyces and focal changes of the ribs. Soft tissue extrarenal findings included diffuse or focal RP hyperfixation within breasts (29 patients), thyroid glands (15), myocardium (5), scrotum (4) and abdominal cavity (4). Symmetrical increased RP accumulation in breast or thyroid lobes was accepted as normal. Pathologic soft tissue findings in 11 patients were verified by history or instrumental data: breast cancer (2), testicular cancer (1), nodular goiter (2), uterine fibroids (2), primary cancer with liver metastases (1), association of "hot kidney" phenomenon with chemotherapy (2), and "superscan" phenomenon with myelofibrosis (1). Causes of radiotracer artifacts in the liver and spleen (14) were of radiopharmaceutical factors, in axillary lymph node (7) – partially infiltrative radiopharmaceuticals administration, in the colon (1) – previous myocardial perfusion scintigraphy. Conclusion. Analysis and interpretation of abnormal extraosseous findings in skeletal scintigraphy is an essential component of additional diagnostic information, that can influence subsequent diagnostic and therapeutic tactics.

1. Subramanian G., McAfee J.G. A new complex of 99mTc for skeletal imaging. Radiology. 1971; 99 (1): 192–6.

2. Zuckier L.S., Martineau P. Altered biodistribution of radiopharmaceuticals used in bone scintigraphy. Semin. Nucl. Med. 2015; 45 (1): 81–96.

3. Loutfi I., Collier B.D., Mohammed A.M. Nonosseous abnormalities on bone scans. J. Nucl. Med. Technol. 2003; 31 (3): 149–53.

4. Сервули Е.А., Страбыкина Д.С., Кондаков А.К., Мосин Д.Ю., Знаменский И.А. Пример анализа возможных причин возникновения артефактов при исследовании костей скелета с применением остеотропных радиофармпрепаратов на основании клинического случая. Медицинский алфавит. Диагностическая радиология и онкотерапия. 2013; 1–2: 25–6. [Servuli E.A., Strabykina D.S., Kondakov A.K., Mosin D.Yu., Znamenskiy I.A. Example of analysis of possible causes of the artifacts in skeletal study with osteotropic radiopharmaceuticals based on the clinical case. Meditsinskiy Alfavit. Diagnosticheskaya Radiologiya i Onkoterapiya. 2013; 1–2: 25–6. (In Russ.)]

5. Сервули Е.А., Страбыкина Д.С., Кондаков А.К., Мосин Д.Ю., Зна- менский И.А. Роль ОФЭКТ/КТ в диагностике внекостной ано- мальной гиперфиксации 99м-Тс пирофосфата. Клинический слу- чай. Вестник РНЦРР МЗ РФ. 2013; 14 (1): 1–10. [Servuli E.A., Strabykina D.S., Kondakov A.K., Mosin D.Yu., Znamenskiy I.A. Role of SPECT/CT in the diagnosis of abnormal extraosseous 99mTcpyrophosphate hyperfixation. Clinical case. Vestnik RNTsRR MZ RF. 2013; 14 (1): 1–10. (In Russ.)]

6. Sato T., Yoshioka S., Ogata Y., Abe Y., Takahashi J., Yamada K. et al. Analysis of contributing factors with high renal uptake of 99mTc-MDP after anti-cancer chemotherapy including cisplatin. Kaku Igaku. 1996; 33 (11): 1221–6.

7. Wulfeck D.W., Sakow N.K., Senler S. Detection of recurrent renal cell carcinoma by three-phase bone scan. Clin. Nucl. Med. 1993; 18 (5): 441–3.

8. Tuncel M., Akdemir E. 99mTcMDP uptake in thyroid nodule: contribution of SPECT-CT and ultrasonography. Rev. Esp. Med. Nucl. Imagen Mol. 2012; 31 (1): 49–50.

9. Rehm P.K., Sharma S. Focal thyroid uptake on bone scan due to thyroid biopsy. Clin. Nucl. Med. 2004; 29 (12): 849–51.

10. Caobelli F., Paghera B., Pizzocaro C., Guerra U.P. Extraosseous myocardial uptake incidentally detected during bone scan: report of three cases and a systematic literature review of extraosseous uptake. Nucl. Med. Rev. Cent. East. Eur. 2013; 16 (2): 82–7.

11. Kawase T., Fujii H., Nakahara T., Shigematsu N., Kubo A., Kosuda S. Intense accumulation of Tc-99m MDP in pericardial metastasis from breast cancer. Clin. Nucl. Med. 2009; 34 (3): 173–4.

12. Chen M., Liu C., Yang J. Intense splenic 99mTc-MDP uptake in a patient with myelofibrosis. Clin. Nucl. Med. 2013. 38 (12): 1022–4.

13. Selcuk N.A., Sayman H.B., Kanmaz B., Turkmen C., Selcuk H., Nisli C. et al. Significance of increased scrotal Tc-99m MDP uptake in patients with prostate cancer. Nucl. Med. Commun. 2011; 32 (2): 155–8. 14. Zaman M.U., Fatima N., Sajjad Z., Hashmi I., Khan K. Higher scrotal uptake ratio of (99m)Tc-MDP on bone scans in newly diagnosed prostate cancer: a reliable indicator of pelvic node metastasis. Ann. Nucl. Med. 2012; 26 (8): 676–80.

14. Teixeira A.B., Etchebehere C.S., Carvalho D.C., Sousa M.C., Santos A.O., Lima M.C. et al. Tc-99m MDP uptake in uterine leiomyoma. Clin. Nucl. Med. 2000; 25 (6): 484.

15. Vriens D., de Geus-Oei L.F., Flucke U.E., van der Kogel A.J., Oyen W.J., Vierhout M.E. et al. Benign uterine uptake of FDG: a case report and review of literature. Neth. J. Med. 2010; 68 (9): 379–80.

16. MacDonald J. Idiopathic hepatic uptake of (99m)Tc methylene diphosphonate: a case report. J. Nucl. Med. Technol. 2001; 29 (1): 32–6.

17. Shih W.J., Han J.K., Magoun S., Wierzbinski B. Bone agent localization in hepatic metastases. J. Nucl. Med. Technol. 1999; 27 (1): 38–40.

18. Flynn B.M., Treves S.T. Diffuse hepatic uptake of technetium-99m methylene diphosphonate in a patient receiving high dose methotrexate. J. Nucl. Med. 1987; 28 (4): 532–4.

19. Zhang W., Chen B., Deng H., Yang T., Ou X. Hepatic and splenic uptake on bone scintigraphy in patients with intravenous administration of 99mTc methylene diphosphonate prior to gadolinium-containing contrast. Clin. Nucl. Med. 2013; 38 (3): 219–20.

20. Endo H., Hashimoto T., Fujioka M., Murata K. A case of metastatic breast cancer showing extraosseous accumulation of 99mTc-HMDP in axillary lymph nodes on bone scintigraphy. Nihon Igaku Hoshasen Gakkai Zasshi. 2001; 61 (13): 730–2.

21. Takahashi T., Machida K., Honda N., Hosono M., Oku S., Osada H. et al. Extraosseous accumulation of 99mTc-MDP in lymph node metastases of small cell carcinoma of the esophagus. Ann. Nucl. Med. 2004; 18 (2): 157–60.

22. Kim S.J., Choi J.Y., Lee J.H., Hyun S.H., Cho Y.S., Moon S.H. Association of Incidental Tc-99m MDP Uptake on Intestine With Intravenous CT Contrast. J. Nucl. Med. 2014; 55 (Suppl. 1): 1984.

23. Ergun E.L., Kiratli P.O., Gunay E.C., Erbas B. A report on the incidence of intestinal 99mTc-methylene diphosphonate uptake of bone scans and a review of the literature. Nucl. Med. Commun. 2006; 27 (11): 877–85.

24. Martinez-Sanchis B., Cortes-Vizcaino V., Frontado-Morales L., Sopena-Novales P. Intestinal uptake of (99m)Tc-MDP: a case report of protein-losing enteropathy correlated with pathology findings from autopsy. Ann. Nucl. Med. 2011. 25 (2): 139–41.